no identified genetic cause. Recently, an international consortium, GLIOGENE, was established to study the genetic basis of familial gliomas. 11
PATHOL OGIC A L FE AT UR ES
Malignant gliomas are histologically heterogeneous and invasive tumors that are derived from glia. The World Health Organization (WHO) classifies astrocytomas on the basis of histologic features into four prognostic grades: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), and grade IV (glioblastoma). 1 Grade III and IV tumors are considered malignant gliomas. Anaplastic astrocytomas are characterized by increased cellularity, nuclear atypia, and mitotic activity. Glioblastomas also contain areas of microvascular proliferation, necrosis, or both ( Fig. 1 and 2 ). Uncommon glioblastoma variants include gliosarcomas, which contain a prominent sarcomatous element; giantcell glioblastomas, which have multinucleated giant cells; small-cell glioblastomas, which are associated with amplification of the epidermal growth factor receptor (EGFR); and glioblastomas with oligodendroglial features, which may be associated with a better prognosis than standard glioblastomas. 1, 12 Oligodendrogliomas are divided by the WHO into two grades: well-differentiated oligodendrogli omas and oligoastrocytomas (WHO grade II), and anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (WHO grade III) ( Fig. 1) . All of these tumors may contain perinuclear halos (Fig. 2C ) and a delicate network of branching blood vessels (chicken-wire pattern). 1 Malignant gliomas typically contain both neoplastic and stromal tissues, which contribute to their histologic heterogeneity and variable outcome. Molecular studies such as gene-expression profiling potentially allow for better classification of these tumors and separation of the tumors into different prognostic groups. [13] [14] [15] [16] [17] 
MOLECUL A R PATHOGENESIS
Recently, there has been important progress in our understanding of the molecular pathogenesis of malignant gliomas, and especially the importance of cancer stem cells. 18, 19 Malignant transformation in gliomas results from the sequential accumulation of genetic aberrations and the deregulation of growth-factor signaling pathways ( Fig. 1   and 3) . 18, 22 Glioblastomas can be separated into two main subtypes on the basis of biologic and genetic differences. 18, 22 Primary glioblastomas typically occur in patients older than 50 years of age and are characterized by EGFR amplification and mutations, loss of heterozygosity of chromosome 10q, deletion of the phosphatase and tensin homologue on chromosome 10 (PTEN), and p16 deletion. Secondary glioblastomas are manifested in younger patients as low-grade or anaplastic astrocytomas and transform over a period of several years into glioblastomas. These tumors, which are much less common than primary glioblastomas, are characterized by mutations in the p53 tumorsuppressor gene, 23 overexpression of the plateletderived growth factor receptor (PDGFR), abnormalities in the p16 and retinoblastoma (Rb) pathways, and loss of heterozygosity of chromosome 10q. 18, 24 Secondary glioblastomas have transcriptional patterns and aberrations in the DNA copy number that differ markedly from those of primary glioblastomas. 18, 22 Despite their genetic differences, primary and secondary glioblastomas are morphologically indistinguishable and respond similarly to conventional therapy, but they may respond differently to targeted molecular therapies.
High-grade oligodendrogliomas are characterized by the loss of chromosomes 1p and 19q (in 50 to 90% of patients). 1 Progression from lowgrade to anaplastic oligodendroglioma is associated with defects in PTEN, Rb, p53, and cellcycle pathways. 1
Deregulated Growth Factor Signaling
The most common defects in growth-factor signaling involve EGFR and PDGFR (Fig. 3) . 18 Amplification of EGFR occurs almost exclusively in primary glioblastomas and is seen in approximately 40 to 50% of patients with that type of tumor. About half of the tumors with EGFR amplification express a constitutively autophosphorylated variant of EGFR, known as EGFRvIII, that lacks the extracellular ligand-binding domain (exons 2 through 7). 14,18 This characteristic variant has become an important therapeutic target for kinase inhibitors, immunotoxins, and peptide vaccines. 3, 18 Recently, activating mutations in the extracellular domain of EGFR have been identified. 25 PDGF signaling is a key regulator of glial development, 26 and both ligand and receptors are frequently expressed in gliomas, creating an autocrine loop that stimulates proliferation of the tumor. 18 Growth factor-receptor signaling, through intermediate signal-transduction generators, results in the activation of transcriptional programs for survival, proliferation, invasion, and angiogenesis. Common signal-transduction pathways activated by these growth factors are the Rasmitogen-activated protein (MAP) kinase pathway, which is involved in proliferation and cellcycle progression, and the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathways, which are involved in the inhibition of apoptosis and cellular proliferation (Fig. 3) . 18 PTEN, a tumor-suppressor gene that negatively regulates the PI3K pathway, is inactivated in 40 to 50% of patients with glio blastomas. 18,27 Many of the above pathways lead to the upregulation of vascular endothelial growth factor (VEGF) and angiogenesis. 28,29 EGFR, PDGFR, and VEGF-receptor (VEGFR) pathways also play an important role in the normal development of the nervous system by promoting the proliferation of multipotent stem cells. Other developmental pathways that contribute to the biologic features of gliomas are those involving sonic hedgehog, wingless, Notch, CXC chemokine receptor 4 (CXCR4), and bone morphogenetic proteins. 19 In addition, oligodendrocyte transcription factor 2 (Olig2), a developmentally regulated, lineage-restricted neural transcription factor, is a universal marker of diffuse gliomas and stem cells that may be a prerequisite for early transformation. 30 Drugs that target these pathways are under active investigation as treatment for gliomas.
Role of Stem Cells in Pathogenesis and Resistance to Therapy
Although the genetic and signaling pathways involved in the development of malignant gliomas Figure 1 . Pathways in the Development of Malignant Gliomas. Genetic and chromosomal alterations involved in the development of the three main types of malignant gliomas (primary and secondary glioblastomas and anaplastic oligodendroglioma) are shown. Oligodendrocyte transcription factor 2 (Olig2) (blue) and vascular endothelial growth factor (VEGF) (red) are expressed in all high-grade gliomas. Median lengths of survival (asterisks) are shown. A slash indicates one or the other or both. DCC denotes deleted in colorectal carcinoma, EGFR epidermal growth factor receptor, LOH loss of heterozygosity, MDM2 murine double minute 2, PDGF platelet-derived growth factor, PDGFR platelet-derived growth factor receptor, PI3K phosphatidylinositol 3-kinase, PTEN phosphatase and tensin homologue, and RB retinoblastoma. by escaping the mechanisms that control proliferation and programmed differentiation (Fig.  4) . [32] [33] [34] [35] [36] These stem cells are identified by several immunocytochemical markers, such as CD133, a glycoprotein also known as prominin 1. 26,32,35,37 Although stem cells account for only a minority of the cells within malignant gliomas, they appear to be critical for generating these tumors. 36, 38 Recent studies suggest that glioma stem cells produce VEGF and promote angiogenesis in the tumor microenvironment. 39 In addition, tumor stem cells appear to require a vascular niche for optimal function. 40 These observations raise the possibility that antiangiogenic therapy may inhibit the functioning of glioma stem cells. There is growing evidence that glioma stem cells may contribute to the resistance of malignant gliomas to standard treatments (Fig. 4) . Radioresistance in stem cells generally results from the preferential activation of DNA-damageresponse pathways, 41 whereas chemoresistance results partly from the overexpression of O 6 -methylguanine−DNA methyltransferase (MGMT), the up-regulation of multidrug resistance genes, and the inhibition of apoptosis. 42-44 Therapeutic strategies that effectively target stem cells and overcome their resistance to treatment will be necessary if malignant gliomas are to be completely eradicated (Fig. 4) . A better understanding of the biologic differences between normal and cancer stem cells will be required to develop selective therapies that spare normal brain cells.
DI AGNOSIS

Clinical Presentation
Patients with malignant gliomas may present with a variety of symptoms, including headaches, seizures, focal neurologic deficits, confusion, memory loss, and personality changes. Although the classic headaches that are suggestive of increased intracranial pressure are most severe in the morning and may wake the patient from sleep, many patients experience headaches that are indistinguishable from tension headaches. When severe, the headaches may be associated with nausea and vomiting.
Imaging
The diagnosis of malignant gliomas is usually suggested by magnetic resonance imaging (MRI) or computed tomography. These imaging studies typically show a heterogeneously enhancing mass with surrounding edema. Glioblastomas frequently have central areas of necrosis and more extensive peritumoral edema than that associated with anaplastic gliomas. 45 Functional MRI may help define the relationship of speech and motor areas to the tumor and aid in the planning of surgery. Diffusion-weighted imaging, diffusion tensor imaging, dynamic contrast-enhanced MRI to measure vessel permeability, and perfusion imaging to measure relative cerebral blood volume are increasingly used as diagnostic aids and as a means of monitoring the response to therapy. 46
Figure 3 (facing page). Major Signaling Pathways in Malignant Gliomas and the Corresponding Targeted
Agents in Development for Glioblastoma. RTK inhibitors that target epidermal growth factor (EGF) receptor include gefitinib, erlotinib, lapatinib, BIBW2992, and vandetanib; those that target plateletderived growth factor (PDGF) receptor include imatinib, dasatinib, and tandutinib; those that target vascular endothelial growth factor (VEGF) receptor include cediranib, pazopanib, sorafenib, sunitinib, vatalanib, vandetanib, and XL184. EGF receptor antibodies include cetuximab and panitumumab. Farnesyl transferase inhibitors include lonafarnib and tipifarnib; HDAC inhibitors include depsipeptide, vorinostat, and LBH589; PI3K inhibitors include BEZ235 and XL765; mTOR inhibitors include sirolimus, temsirolimus, everolimus, and deforolimus; and VEGF receptor inhibitors include bevacizumab, aflibercept (VEGF-trap), and CT-322. Growth factor ligands include EGF, PDGF, IGF, TGF, HGF/SF, VEGF, and FGF. Stem-cell pathways include SHH, wingless family, and Notch. Akt denotes murine thymoma viral oncogene homologue (also known as protein kinase B), CDK cyclin-dependent kinase, ERK extracellular signal-regulated kinase, FGF fibroblast growth factor, FTI farnesyl transferase inhibitors, GDP guanine diphosphate, Grb 2 growth factor receptor-bound protein 2, GTP guanine triphosphate, HDAC histone deacetylase, HGF/SF hepatocyte growth factor/scatter factor, IGF insulin-like growth factor, MEK mitogen-activated protein kinase kinase, mTOR mammalian target of rapamycin, NF1 neurofibromin 1, PIP2 phosphatidylinositol (4, 5) biphosphate, PIP3 phosphatidylinositol 3,4,5-triphosphate, PI3K phosphatidylinositol 3-kinase, PKC protein kinase C, PLC phospholipase C, PTEN phosphatase and tensin homologue, RAF v-raf 1 murine leukemia viral oncogene homologue 1, RAS rat sarcoma viral oncogene homologue, RTK receptor tyrosine kinase inhibitor, SHH sonic hedgehog, SOS son of sevenless, Src sarcoma (Schmidt-Ruppin A-2) viral oncogene homologue, TGF transforming growth factor family, and TSC1 and 2 tuberous sclerosis gene 1 and 2. Red text denotes inhibitors. Data are from Sathornsumetee et al., 3 Furnari et al.,  18 Chi and Wen, 20 and Sathornsumetee et al.
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The New Proton magnetic resonance spectroscopy detects the levels of metabolites and may help differentiate a tumor from necrosis or benign lesions. In patients with malignant gliomas, this imaging technique typically shows an increase in the choline peak (reflecting increased membrane turnover) and a decrease in the N-acetyl aspartate peak (reflecting decreased neuronal cellularity), as compared with the findings in unaffected areas of the brain. 45, 46 Positron-emission tomography that uses isotopes such as 18 F-fluorodeoxyglucose, 18 F-fluoro-l-thymidine, 11 C-methionine, and 3,4-dihydroxy-6-18 F-fluoro-l-phenylalanine is being evaluated for its usefulness in diagnosis and in monitoring the response to therapy. 47 In up to 40% of cases, the MRI studies that are performed in the first month after radiotherapy show increased enhancement. 48 In 50% of these cases, the increased enhancement reflects a transient increase in vessel permeability as a result of radiotherapy, a phenomenon termed "pseudoprogression," which improves with time. 48 Differen- tiating this transient effect from true progression of the cancer can be challenging initially, even with advanced imaging techniques.
TR E ATMENT
General Medical Management
Much of the care of patients with malignant gliomas involves general medical management.
The most common problems include seizures, peritumoral edema, venous thromboembolism, fatigue, and cognitive dysfunction. 49 Patients who present with seizures should be treated with antiepileptic drugs. Since antiepileptic drugs that induce hepatic cytochrome P-450 enzymes, such as phenytoin and carbamazepine, increase the metabolism of many chemotherapeutic agents, antiepileptic drugs that do not induce these enzymes, such as levetiracetam, are generally preferred. The use of prophylactic antiepileptic drugs in patients with malignant gliomas who have never had a seizure is controversial. The American Academy of Neurology issued a practice guideline indicating that there is no evidence that prophylactic antiepileptic drugs are beneficial and advises against the routine use of antiepileptic drugs in patients with brain tumors who have not had seizures. 50 Corticosteroids such as dexamethasone are frequently used to treat peritumoral edema. Cushing's syndrome and corticosteroid myopathy may develop in patients who require prolonged treatment with high doses of corticosteroids. Patients with brain tumors who receive corticosteroids are at increased risk for Pneumocystis jiroveci pneumonitis, and prophylactic antibiotic therapy should be considered, 49 although a recent meta-analysis did not show a benefit from this approach. 51 As the rate of survival among patients with malignant glioma improves, long-term complications from treatment with corticosteroids, including osteoporosis and compression fractures, are becoming increasingly evident, and preventive measures, such as treatment with vitamin D, calcium supplements, and bisphosphonates, should be considered. Novel therapies such as corticotropinreleasing factor, bevacizumab (a humanized VEGF monoclonal antibody), and VEGFR inhibitors decrease peritumoral edema and may reduce the need for corticosteroids. 49, 52 Patients with malignant gliomas are at increased risk for venous thromboembolism from leg and pelvic veins, with a cumulative incidence of 20 to 30%. 49, 53 The risk of intratumoral hemorrhage associated with anticoagulation therapy in patients with gliomas who have venous thromboembolism is low, 49,54 whereas inferior vena cava filters are associated with high complication rates. 55 Unless a patient with malignant glioma and venous thromboembolism has an intracerebral hemorrhage or other contraindications, it is generally safe to provide anticoagulation therapy for the venous thromboembolism. Low-molecularweight heparin may be more effective and safer than warfarin. 56 Patients with malignant gliomas frequently experience fatigue and may benefit from treatment with modafinil or methylphenidate. 57 Methylphenidate may also help abulia, and donepezil 58 and memantine may reduce memory loss, although evidence supporting these approaches remains limited. Depression is underdiagnosed in patients with malignant gliomas, and antidepressants and psychiatric support are often invaluable. 59
Specific Therapy for Newly Diagnosed Malignant Gliomas
The standard therapy for newly diagnosed malignant gliomas involves surgical resection when feasible, radiotherapy, and chemotherapy (Table 1) . Malignant gliomas cannot be completely eliminated surgically because of their infiltrative nature, but patients should undergo maximal surgical resection whenever possible. Surgical debulking reduces the symptoms from mass effect and provides tissue for histologic diagnosis and molecular studies. Advances such as MRI-guided neuronavigation, intraoperative MRI, functional MRI, intraoperative mapping, 60 and fluorescence-guided surgery 61 have improved the safety of surgery and increased the extent of resection that can be achieved. The value of surgery in prolonging survival is controversial, but patients who undergo extensive resection probably have a modest survival advantage. 60-62 Stereotactic biopsies should be performed only in patients who have inoperable tumors that are located in critical areas.
Radiotherapy is the mainstay of treatment for malignant gliomas. The addition of radiotherapy to surgery increases survival among patients with glioblastomas from a range of 3 to 4 months to a range of 7 to 12 months. 63,64 Conventional radiotherapy consists of 60 Gy of partial-field external-beam irradiation delivered 5 days per week in fractions of 1.8 to 2.0 Gy. After standard radio- Patients who are older than 70 years of age have a worse prognosis than younger patients and represent a particular challenge. Among these patients, radiotherapy produces a modest benefit in median survival (29.1 weeks) as compared with supportive care (16.9 weeks). 71 Since older patients often tolerate radiotherapy less well than younger patients, an abbreviated course of radiotherapy (40 Gy in 15 fractions over a period of 3 weeks) 72 or chemotherapy with temozolomide (an oral alkylating agent with good penetration of the blood-brain barrier) alone 73 may be considered, since the outcomes with these approaches are similar to the outcomes with conventional radiotherapy regimens.
Chemotherapy is assuming an increasingly important role in the treatment of malignant gliomas. Although early studies of adjuvant chemotherapy for malignant gliomas with the use of nitrosoureas failed to show a benefit, 63,74 two metaanalyses have suggested that adjuvant chemotherapy results in a modest increase in survival (a 6 to 10% increase in the 1-year survival rate). 75, 76 The European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) conducted a phase III trial comparing radiotherapy alone (60 Gy over a period of 6 weeks) with radiotherapy and concomitant treatment with temozolomide (75 mg per square meter of body-surface area per day for 6 weeks), followed by adjuvant temozolomide therapy (150 to 200 mg per square meter per day for 5 days every 28 days for 6 cycles), in patients with newly diagnosed glioblastomas. 64 As reported by Stupp et al., the combination of radiotherapy and temozolomide had an acceptable side-effect profile and, as compared with radiotherapy alone, increased the median survival (14.6 months vs. 12.1 months, P<0.001). 64 In addition, the survival rate at 2 years among the patients who received radiotherapy and temozolomide was significantly greater than the rate among the patients who received radiotherapy alone (26.5% vs. 10.4%), 64 establishing radiotherapy with concomitant and adjuvant temozolomide as a useful combination for newly diagnosed glioblastomas.
MGMT is an important repair enzyme that contributes to resistance to temozolomide. In a companion study to the EORTC-NCIC study reported by Stupp et al., tumor specimens from the pa- Another chemotherapeutic approach involves the implantation of biodegradable polymers containing carmustine (Gliadel Wafers, MGI Pharma) into the tumor bed after resection of the tumor. The aim of treatment with these polymers, which release carmustine gradually over the course of several weeks, is to kill residual tumor cells. In a randomized, placebo-controlled trial that investigated the use of these polymers in patients with newly diagnosed malignant gliomas, median survival increased from 11.6 months to 13.9 months (P = 0.03). 77 This survival advantage was maintained at 2 and 3 years. 78
Therapy for Anaplastic Gliomas
Anaplastic astrocytomas are treated with radiotherapy and either concurrent and adjuvant temozolomide (as for glioblastomas) or adjuvant temozolomide alone. Currently, there are no findings from controlled trials that support the use of concurrent temozolomide in patients with anaplastic astrocytomas.
Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas are an important subgroup of malignant gliomas that are generally more responsive to therapy than are pure astrocytic tumors. 79 A codeletion of chromosomes 1p and 19q, 79 mediated by an unbalanced translocation of 19p to 1q, 80 occurs in 61 to 89% of patients with anaplastic oligodendrogliomas and 14 to 20% of patients with anaplastic oligoastrocytomas. Tumors in patients with the 1p and 19q codeletion are particularly sensitive to chemotherapy with PCV -procarbazine, lomustine (CCNU), and vincristine -with response rates of up to 100%, as compared with response rates of 23 to 31% among patients without the deletion of chromosomes 1p and 19q. 81, 82 The reason for the increased chemosensitivity of tumors in patients with the 1p and 19q codeletion is unclear. One study suggested that 1p loss is associated with decreased levels of stathmin and an increased sensitivity to nitrosoureas. 83 The status of chromosomes 1p and 19q, rather than standard histologic assessment, is now used as an eligibility criterion in studies involving patients with anaplastic oligodendrogliomas and anaplastic oligoastrocytomas, reflecting a paradigm shift in the design of clinical trials for patients with these tumors.
Two large phase III studies of PCV chemotherapy with radiotherapy, as compared with radiotherapy alone, in patients with newly diagnosed anaplastic oligodendrogliomas or anaplastic oligoastrocytomas, have been reported. 84, 85 In both studies, the addition of chemotherapy to radiotherapy increased the time to tumor progression by 10 to 12 months but did not improve overall survival (median, 3.4 and 4.9 years). 84, 85 The failure of chemotherapy to increase survival may be partly explained by the fact that patients who initially received radiotherapy alone subsequently received chemotherapy when they had a relapse, so that most patients in both groups eventually received chemotherapy. In both studies, patients with the codeletion of 1p and 19q had improved survival as compared with those without the codeletion of 1p and 19q. Although most studies involving patients with anaplastic oligodendrogliomas or anaplastic oligoastrocytomas were conducted with PCV chemotherapy, temozolomide is likely to have similar activity and less toxicity 79 ; however, studies directly comparing the two regimens have not been performed.
Therapy for Recurrent Malignant Gliomas
Despite optimal treatment, nearly all malignant gliomas eventually recur. For glioblastomas, the median time to progression after treatment with radiotherapy and temozolomide is 6.9 months. 
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operation may be indicated (Table 1) . However, surgery performed in selected patients results in only limited prolongation of survival. 86 The usefulness of radiotherapy for recurrent malignant gliomas is controversial. 87 Although some reports have suggested that fractionated stereotactic reirradiation 88 and stereotactic radiosurgery 68 may be beneficial, selection bias may have influenced these results.
The value of conventional chemotherapy for recurrent malignant gliomas is modest. In general, chemotherapy is more effective for anaplastic gliomas than for glioblastomas. 79,87 Temozolomide was evaluated in a phase II study involving patients with recurrent anaplastic gliomas who had previously been treated with nitrosoureas; the study showed a 35% response rate. The 6-month rate of progression-free survival was 46%, 89 comparing favorably with the 31% rate of progressionfree survival at 6 months for therapies that were reported to be ineffective. 90 In contrast, temozolomide has only limited activity in patients with recurrent glioblastomas (response rate, 5.4%; 6-month rate of progression-free survival, 21%). 91 Other chemotherapeutic agents that are used for recurrent gliomas include nitrosoureas, carboplatin, procarbazine, irinotecan, and etoposide. Carmustine wafers have modest activity, increasing the median survival by approximately 8 weeks in patients with recurrent glioblastomas. 92 
IN V ES TIGATIONA L THER A PIES
Targeted Molecular Therapies
The improved understanding of the molecular pathogenesis of malignant gliomas has allowed a more rational use of targeted molecular therapies (Fig. 3) . 18, 20, 21 Particular interest has focused on inhibitors that target receptor tyrosine kinases such as EGFR, 93 PDGFR, 94 and VEGFR, 52 as well as on signal-transduction inhibitors targeting mTOR, 95,96 farnesyltransferase, 97 and PI3K (Table 2). Single agents have only modest activity, with response rates of 0 to 15% and no prolongation of 6-month progression-free survival. 3, 20, 21 These disappointing results are due to several factors. Most malignant gliomas have coactivation of multiple tyrosine kinases, 98 as well as redundant signaling pathways, thus limiting the activity of single agents. In addition, many of these agents have poor penetration across the blood−tumor barrier. There has been considerable interest in identifying molecular features of the tumor that predict a response, so that patients who are most likely to benefit can be selected for a particular treatment. EGFR inhibitors appear to be more effective in patients who have tumors with EGFRvIII mutations and intact PTEN than in patients who do not have these molecular changes 99 ; patients who have tumors with increased activity of the PI3K-Akt pathway, as indicated by an increase in phosphorylated Akt, generally do not have a response. 100 Current experimental strategies to increase the effectiveness of targeted molecular therapies include the use of a single agent targeted against several kinases, combinations of agents that inhibit complementary targets such as EGFR and mTOR (Table 2 and Fig. 5A through 5D ), and targeted agents combined with radiotherapy and chemotherapy. 3, 18, 20, 21 
Antiangiogenic Agents
Malignant gliomas are among the most vascular of human tumors, 18 making them especially attractive targets for angiogenesis inhibitors. 29 Although older antiangiogenic agents such as thalidomide had only modest activity, 101 newer and more potent angiogenesis inhibitors show promising activity. In preliminary studies, treatment with the combination of bevacizumab and irinotecan was associated with a low incidence of hemorrhage and response rates of 57 to 63% among patients with malignant gliomas (Fig. 5E through  5H) . 102, 103 Some of the improvement that is seen on radiographic images may be artifactual, caused by reduced vascular permeability and decreased contrast enhancement as a result of the inhibition of VEGF. However, this regimen also has antitumor activity, as evidenced by the fact that it increased the 6-month rate of progression-free survival to 46% among patients with recurrent glioblastomas, 102, 103 as compared with a 6-month rate of progression-free survival of 21% for patients who were receiving treatment with temozolomide. 91 Recently, a large, randomized phase II trial of bevacizumab alone and bevacizumab with irinotecan was completed. Preliminary results confirmed the safety of bevacizumab and showed an increase in the 6-month rate of progression-free survival to 35.1% for patients receiving bevacizu- 
SUMM A R Y
Recently, there has been important progress in the treatment of malignant gliomas 111 and in our understanding of the molecular pathogenesis of these tumors and the critical role that stem cells play in their development and resistance to treatment. As our understanding of the molecular correlates of response improves, it may be possible to select the most appropriate therapies on the basis of the patient's tumor genotype. These advances provide real opportunities for the development of effective therapies for malignant gliomas.
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